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Review of Cases of Carcinoid Tumors and Neuroendocrine Carcinoma Diagnosed at Lehigh 
Valley Health Network From 2011-2015
• Carcinoid tumors and neuroendocrine carcinomas can 
arise in any tissue. Carcinoid tumors are often low grade 
in comparison to neuroendocrine carcinomas which 
behave like small cell carcinoma of the lung.
• For local/local regional carcinoid or neuroendocrine 
carcinoma, surgery is the initial treatment 
recommended. 
• For stage IV carcinoid  tumor, treatment is 
recommended if the patient is symptomatic. Octreotide 
therapy is recommended for carcinoid syndrome 
(diarrhea, facial flushing, and shortness of breath.)
• For stage IV neuroendocrine carcinoma, palliative 
chemotherapy is recommended.  
• The goals of this study were to determine whether 
treatments offered to patients treated at LVHN from 
2011-2015 were in compliance with the the National 
Comprehensive Cancer Network version 3.2017 
(NCCN) Guidelines and to determine the overall survival 
of these patients. 





• Treatment offered for carcinoid and neuroendocrine 
carcinoma at LVHN followed NCCN guidelines.
• Age of diagnosis ranged from 18-93 years and the 
average age of diagnosis was 63.3 years for carcinoid 
tumor and 66.7 years for neuroendocrine carcinoma. 
• Carcinoid tumors had an overall higher survival rate 
than neuroendocrine carcinomas as expected.
• The majority of patients with stages I-III of carcinoid 
and neuroendocrine carcinoma actually died of other 
causes than their neuroendocrine cancer. 
• A higher stage of cancer was correlated to a higher rate 
of mortality for both tumor types REFERENCES
National Comprehensive Cancer Network. Neuroendocrine Tumors(Version 
3.2017). https://www.nccn.org/professionals/physician_gls/pdf/neuroendoc
rine.pdf Accessed 20 June, 2017.
Figure 2. (above) Overall survival of carcinoid tumors and neuroendocrine carcinoma. 
Neuroendocrine carcinoma tumors tend to be more aggressive than carcinoid tumors.  
Stage I Stage II Stage III Stage IV
Carcinoid Tumor 95% 96 % 87% 71%
Neuroendocrine 
Carcinoma
95% 33% 78% 25%
Table 1. above) Survival of carcinoid tumor and neuroendocrine carcinoma by stage. With the 
exception of stage 2 neuroendocrine carcinoma, With the exception of stage II 
neuroendocrine carcinoma, these survival rates are similar to the national average.  
Figure 3. (left) low 
survival rates of 
neuroendocrine 
carcinoma are attributed 
to  a small sample size 
and mortality from 
comorbidities such as 
heart disease and stroke.  
137 cases of carcinoid tumor 
and 99 cases of 
neuroendocrine carcinoma 
were diagnosed at LVHN 
between 2011 and 2015.
25 cases were dropped from final 
analysis.
One patient was pediatric.
24 cases lacked staging information.     
123 carcinoid tumors and 89 
neuroendocrine carcinomas were 
included in the final analysis. 
Age at the time of diagnosis, cancer 
morphology, and overall survival based 
on treatment and staging were 
analyzed in this study. 
Figure 1. (above) Types of treatment received by carcinoid tumor and 
neuroendocrine carcinoma patients. Treatments offered by LVHN follow the 
NCCN guidelines 
